elraglusib   Click here for help

GtoPdb Ligand ID: 11412

Synonyms: 9-ING-41 | compound 26 [PMID: 19338355]
Compound class: Synthetic organic
Comment: This entry was generated using the chemical structure that was submitted to the WHO for INN elraglusib. In that submission it is described as a glycogen synthase kinase inhibitor. The chemical structure also matches that of 9-ING-41 [2] which is a maleimide-based GSK-3 inhibitor [1] and an oncology clinical lead.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES Fc1ccc2c(c1)c(co2)C1=C(C(=O)NC1=O)c1cn(c2c1cc1OCOc1c2)C
Isomeric SMILES Fc1ccc2c(c1)c(co2)C1=C(C(=O)NC1=O)c1cn(c2c1cc1OCOc1c2)C
InChI InChI=1S/C22H13FN2O5/c1-25-7-13(11-5-17-18(6-15(11)25)30-9-29-17)19-20(22(27)24-21(19)26)14-8-28-16-3-2-10(23)4-12(14)16/h2-8H,9H2,1H3,(H,24,26,27)
1. Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD et al.. (2009)
From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
J Med Chem, 52 (7): 1853-63. [PMID:19338355]
2. Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD, Mukhopadhyay D. (2014)
Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
Mol Cancer Ther, 13 (2): 285-96. [PMID:24327518]